GO:2000304 positive regulation of ceramide biosynthetic process: Lipid Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000304 describes any process that activates or increases the frequency, rate or extent of ceramide biosynthetic process, a central node in sphingolipid metabolism.
• Ceramide biosynthesis is positively regulated by enzymes such as serine palmitoyltransferase (SPT), ceramide synthases (CerS1-6), and sphingomyelinases, and is modulated by metabolic and inflammatory signals.
• Dysregulation of ceramide biosynthesis contributes to obesity-related metabolic dysfunction, alcohol-associated liver disease, Parkinson's disease, Alzheimer's disease, and cancer progression.
• Key genes involved include SPTLC1/2, KDSR, CERS1-6, DEGS1, SMPD1-3, and ASAH1/2, with tissue-specific roles in liver, brain, and immune cells.
• Experimental models for studying GO:2000304 include CRISPR knockout, point-mutation, knock-in, and overexpression cell lines, as well as CRISPR library screening and multi-omics integration.
• Therapeutic targeting of ceramide biosynthesis is being explored in metabolic diseases, neurodegeneration, and cancer, with exercise and dietary interventions showing modulatory effects.
Description
Ceramide is a bioactive sphingolipid that serves as a structural component of cell membranes and a signaling molecule in stress responses, apoptosis, and metabolic regulation. The Gene Ontology term GO:2000304, positive regulation of ceramide biosynthetic process, encompasses all molecular events that enhance the production of ceramide through the de novo synthesis pathway or sphingomyelin hydrolysis. This process is critical for maintaining lipid homeostasis, and its dysregulation is increasingly linked to human diseases including obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative disorders, and cancer. Understanding the positive regulation of ceramide biosynthesis is therefore essential for researchers investigating lipid signaling, metabolic disease mechanisms, and potential therapeutic targets. The positive regulation of ceramide biosynthetic process involves multiple enzymes and regulatory inputs. Serine palmitoyltransferase (SPT) catalyzes the rate-limiting step, and its activity is modulated by nutrient status, inflammatory cytokines, and hormonal signals. Ceramide synthases (CerS1-6) then acylate sphinganine to form dihydroceramide, which is desaturated by DES1 to yield ceramide. Additionally, sphingomyelinases can generate ceramide via hydrolysis of sphingomyelin, contributing to the pool of bioactive ceramide. Recent studies have shown that intestinal MYC modulates obesity-related metabolic dysfunction by influencing ceramide levels, and ceramide-induced FGF13 impairs systemic metabolic health. These findings highlight the importance of precise regulation of ceramide biosynthesis in physiology and disease. This article provides a research-grade overview of GO:2000304, integrating authoritative QuickGO data with verified PubMed literature. We cover the definition, key genes, regulatory mechanisms, disease associations, and experimental models including CRISPR-based approaches. The content is designed for researchers seeking to understand or manipulate ceramide biosynthesis in cellular and animal models, and for those developing therapeutic strategies targeting this pathway.
positive regulation of ceramide biosynthetic process At A Glance
| GO ID | GO:2000304 |
|---|---|
| GO term | positive regulation of ceramide biosynthetic process |
| Ontology | biological_process |
| Synonym | positive regulation of ceramide anabolism; positive regulation of ceramide biosynthesis; positive regulation of ceramide formation; positive regulation of ceramide synthesis |
| Major function | Upregulation of ceramide production through de novo synthesis or sphingomyelin hydrolysis |
| Related GO terms | regulation of ceramide biosynthetic process (GO:2000303); ceramide biosynthetic process (GO:0046513) |
| Key enzymes | Serine palmitoyltransferase (SPT), ceramide synthases (CerS1-6), dihydroceramide desaturase (DEGS1), sphingomyelinases (SMPD1-3) |
| Disease relevance | Obesity, alcohol-associated liver disease, Parkinson's disease, Alzheimer's disease, breast cancer |
What Is GO:2000304?
GO:2000304, positive regulation of ceramide biosynthetic process, is a biological process term defined as any process that activates or increases the frequency, rate or extent of ceramide biosynthetic process. In other words, it includes all molecular signals and mechanisms that upregulate the production of ceramide, a central sphingolipid involved in membrane structure and signaling. This term is a child of positive regulation of lipid biosynthetic process and regulation of ceramide biosynthetic process, and it specifically covers positive regulatory events, excluding those that decrease ceramide synthesis.
Why Is positive regulation of ceramide biosynthetic process Important in Cell Biology?
The positive regulation of ceramide biosynthetic process is critically important because ceramide acts as a hub for sphingolipid metabolism and signaling, influencing cell fate decisions such as apoptosis, senescence, and insulin resistance. Dysregulated ceramide biosynthesis is a hallmark of metabolic disorders, neurodegeneration, and cancer, making this process a prime target for therapeutic intervention. Understanding how ceramide production is upregulated can reveal novel biomarkers and drug targets, and guide the development of precision medicine approaches for diseases ranging from non-alcoholic fatty liver disease to Parkinson's disease.
• Ceramide accumulation is linked to obesity-related metabolic dysfunction and insulin resistance, with intestinal MYC playing a modulatory role.
• Ceramide-induced FGF13 impairs systemic metabolic health, highlighting a direct signaling axis.
• Dysregulated lipidomic networks involving ceramide are observed in Parkinson's disease patients with TMEM175 mutations.
• Aerobic exercise training alters systemic biomarkers including ceramide species in adults at risk for Alzheimer's disease.
• Neutral ceramidase regulates breast cancer progression by metabolic programming of TREM2-associated macrophages, affecting ceramide levels.
• Peripheral upregulation of ceramide glucosyltransferase is observed in major depression, linking sphingolipid metabolism to mood disorders.
• Cigu Xiaozhi prescription intervenes in ceramide lipoapoptosis in non-alcoholic fatty liver disease, showing therapeutic potential.
• Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in energy homeostasis.
• Targeting ceramide biosynthesis enzymes with CRISPR models can elucidate causal roles in disease and identify new drug targets.
• Multi-omics approaches integrating lipidomics and proteomics are powerful for dissecting ceramide regulatory networks in patient cohorts.
What Happens During positive regulation of ceramide biosynthetic process?
Activation of de novo sphingolipid synthesis
In simple terms: The cell increases the production of ceramide from scratch using simple building blocks.
The de novo pathway begins with the condensation of serine and palmitoyl-CoA by serine palmitoyltransferase (SPT), the rate-limiting enzyme. Positive regulation of this step can occur through increased expression or activity of SPT subunits (SPTLC1, SPTLC2, SPTLC3) in response to metabolic signals such as obesity or alcohol consumption. For example, intestinal MYC modulates obesity-related metabolic dysfunction by influencing ceramide levels, suggesting that MYC can positively regulate SPT or downstream enzymes. In alcohol-associated liver disease, CerS6 is upregulated, which enhances the synthesis of specific ceramide species.
Upregulation of ceramide synthase activity
In simple terms: Enzymes called ceramide synthases add fatty acid chains to make ceramide, and their activity is boosted.
Ceramide synthases (CerS1-6) catalyze the N-acylation of sphinganine to form dihydroceramide, which is then desaturated to ceramide. Positive regulation can involve increased transcription or post-translational activation of specific CerS isoforms. CerS6 is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation. In breast cancer, neutral ceramidase regulates progression by metabolic programming of TREM2-associated macrophages, indirectly affecting ceramide synthase activity.
Sphingomyelin hydrolysis as a positive regulatory input
In simple terms: Ceramide can also be made by breaking down sphingomyelin, and signals that activate this breakdown increase ceramide.
Sphingomyelinases (SMPD1, SMPD2, SMPD3) hydrolyze sphingomyelin to generate ceramide. Positive regulation of this pathway occurs in response to inflammatory cytokines, stress, or death receptor activation. In Parkinson's disease patients with TMEM175 mutations, dysregulated lipidomic networks suggest altered sphingomyelin metabolism. Additionally, peripheral upregulation of ceramide glucosyltransferase in major depression indicates that enzymes interconverting ceramide and complex sphingolipids are subject to regulation.
Integration with metabolic and inflammatory signaling
In simple terms: Hormones, nutrients, and inflammation can turn up ceramide production.
Positive regulation of ceramide biosynthesis is integrated with systemic metabolic signals. Ceramide-induced FGF13 impairs systemic metabolic health, demonstrating a feedback loop where ceramide itself can influence metabolic pathways. Aerobic exercise training alters systemic biomarkers including ceramide species in late middle-aged adults at risk for Alzheimer's disease, indicating that lifestyle interventions can modulate ceramide biosynthesis. Cigu Xiaozhi prescription intervenes in ceramide lipoapoptosis in non-alcoholic fatty liver disease, showing that pharmacological agents can target this process.
Key Genes Involved in GO:2000304 positive regulation of ceramide biosynthetic process
The following genes and proteins are key players in the positive regulation of ceramide biosynthetic process, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPTLC1 | Subunit of serine palmitoyltransferase, rate-limiting enzyme in de novo ceramide synthesis | Target for metabolic disease and neurodegeneration; knockout models show reduced ceramide |
| SPTLC2 | Subunit of serine palmitoyltransferase | Mutations linked to hereditary sensory neuropathy; CRISPR models available |
| SPTLC3 | Subunit of serine palmitoyltransferase | Modulates ceramide species in response to fatty acids |
| KDSR | 3-ketodihydrosphingosine reductase, involved in sphingolipid synthesis | Defects cause skin disorders; relevant to ceramide biosynthesis |
| CERS1 | Ceramide synthase 1, produces C18 ceramide | Linked to neurodegeneration and cancer; knockout models |
| CERS2 | Ceramide synthase 2, produces very long-chain ceramides | Role in liver disease and insulin resistance |
| CERS3 | Ceramide synthase 3, produces long-chain ceramides | Skin barrier function; knockout models |
| CERS4 | Ceramide synthase 4 | Less studied; potential role in cancer |
| CERS5 | Ceramide synthase 5, produces C16 ceramide | Linked to obesity and insulin resistance |
| CERS6 | Ceramide synthase 6, produces C16 ceramide | Upregulated in alcohol-associated liver disease; sex-based differences |
| DEGS1 | Dihydroceramide desaturase, converts dihydroceramide to ceramide | Target for cancer and metabolic disease |
| SMPD1 | Acid sphingomyelinase, hydrolyzes sphingomyelin to ceramide | Defects cause Niemann-Pick disease; role in neurodegeneration |
| SMPD2 | Neutral sphingomyelinase | Involved in stress responses |
| SMPD3 | Neutral sphingomyelinase 2 | Regulates ceramide in brain and bone |
| ASAH1 | Acid ceramidase, degrades ceramide | Opposes positive regulation; target for cancer |
| ASAH2 | Neutral ceramidase | Regulates breast cancer progression via macrophages |
| MYC | Transcription factor, modulates obesity-related metabolic dysfunction | Intestinal MYC affects ceramide levels |
| FGF13 | Fibroblast growth factor 13, induced by ceramide | Impairs systemic metabolic health |
How Is positive regulation of ceramide biosynthetic process Regulated?
The positive regulation of ceramide biosynthetic process is controlled at multiple levels. Transcriptional regulation includes MYC-driven expression of ceramide synthesis genes in the intestine, which modulates obesity-related metabolic dysfunction. Post-translational modifications and allosteric regulation of SPT and CerS enzymes by nutrients and hormones also play key roles. Inflammatory cytokines can activate sphingomyelinases, increasing ceramide production. Additionally, exercise training alters systemic ceramide biomarkers, suggesting that physiological stimuli can regulate this pathway. The process is also influenced by genetic variants, such as TMEM175 mutations in Parkinson's disease that disrupt lipidomic networks.
positive regulation of ceramide biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CERS6 | Alcohol-associated liver disease | CRISPR knockout in hepatocytes; overexpression in mouse liver |
| SMPD1 | Niemann-Pick disease; Parkinson's disease | Point mutation knock-in in iPSCs; knockout in neurons |
| ASAH2 | Breast cancer progression | Knockout in breast cancer cell lines; macrophage co-culture |
| MYC | Obesity-related metabolic dysfunction | Intestinal-specific knockout in mice; overexpression |
| FGF13 | Systemic metabolic health | Knockout and overexpression in adipocytes |
Metabolic dysfunction and obesity
Positive regulation of ceramide biosynthesis contributes to obesity-related metabolic dysfunction. Intestinal MYC modulates this process, and ceramide-induced FGF13 impairs systemic metabolic health. CerS6 is upregulated in alcohol-associated liver disease and exhibits sex-based differences in energy homeostasis. Targeting ceramide synthesis may improve insulin sensitivity and liver function.
Neurodegeneration
Dysregulated ceramide metabolism is observed in Parkinson's disease patients with TMEM175 mutations, and aerobic exercise alters ceramide biomarkers in adults at risk for Alzheimer's disease. Sphingomyelinase defects (e.g., SMPD1) cause Niemann-Pick disease, a lysosomal storage disorder with neurodegeneration. Modulating ceramide biosynthesis could be neuroprotective.
Cancer
Neutral ceramidase regulates breast cancer progression by metabolic programming of TREM2-associated macrophages, affecting ceramide levels. Ceramide synthases and sphingomyelinases are implicated in tumor growth and metastasis. Positive regulation of ceramide biosynthesis may promote apoptosis in cancer cells, making it a therapeutic target.
Liver disease
Cigu Xiaozhi prescription intervenes in ceramide lipoapoptosis in non-alcoholic fatty liver disease, and CerS6 is upregulated in alcohol-associated liver disease. These findings highlight the role of ceramide biosynthesis in hepatic steatosis and injury.
From positive regulation of ceramide biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CERS6 reduce ceramide levels and improve liver function? | CRISPR knockout CERS6 in HepG2 or primary hepatocytes |
| Does a point mutation in SPTLC1 alter enzyme activity? | CRISPR point mutation knock-in in HEK293T cells |
| Can overexpression of SMPD1 increase ceramide and induce apoptosis? | CRISPR knock-in of a doxycycline-inducible SMPD1 cassette |
| What is the role of MYC in intestinal ceramide synthesis? | Intestinal-specific MYC knockout mice |
| Does FGF13 mediate ceramide-induced metabolic impairment? | FGF13 knockout and overexpression in adipocytes |
| Can CRISPR library screening identify regulators of ceramide biosynthesis? | Genome-wide CRISPR knockout library in a ceramide reporter cell line |
How to Study the positive regulation of ceramide biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS lipidomics | Ceramide species concentrations | Quantify changes in cells or tissues |
| CRISPR knockout library screening | Genes that regulate ceramide levels | Identify novel positive regulators |
| RNA-seq | Transcript levels of ceramide synthesis genes | Assess transcriptional upregulation |
| Proteomics | Protein expression and modifications | Discover signaling networks |
| Enzyme activity assay | SPT, CerS, sphingomyelinase activity | Validate direct regulation |
| Immunofluorescence | Subcellular localization of enzymes | Study organelle-specific ceramide synthesis |
| Flow cytometry | Ceramide levels in single cells | Sort cells with altered ceramide |
Lipidomics and mass spectrometry
Quantitative lipidomics using LC-MS/MS is the gold standard for measuring ceramide species. This method can detect changes in ceramide levels upon genetic or pharmacological manipulation, as demonstrated in studies of Parkinson's disease and alcohol-associated liver disease.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify positive regulators of ceramide biosynthesis. Coupling with a ceramide-responsive reporter or mass spectrometry readout allows high-throughput discovery of novel regulators.
Transcriptomics and proteomics
RNA-seq and proteomics can reveal changes in expression of ceramide synthesis enzymes. Multi-omics approaches have identified dysregulated lipidomic and proteomic networks in Parkinson's disease patients.
Enzyme activity assays
In vitro assays for SPT, CerS, and sphingomyelinase activities using radiolabeled substrates or fluorescent probes can directly measure positive regulation. These are often used to validate findings from genetic screens.
How CRISPR Can Be Used to Study GO:2000304 positive regulation of ceramide biosynthetic process
Knockout
CRISPR knockout of genes such as CERS6, SMPD1, or MYC can reduce ceramide biosynthesis and reverse disease phenotypes. For example, CERS6 knockout in hepatocytes may decrease ceramide levels and improve alcohol-associated liver disease. Intestinal MYC knockout mice show altered ceramide levels and metabolic dysfunction.
Point Mutation
Point mutations in SPTLC1 or SMPD1 can mimic human disease variants and alter enzyme activity. CRISPR point mutation knock-in in cell lines allows precise study of how specific amino acid changes affect positive regulation of ceramide biosynthesis.
Knock-in
Knock-in of tagged or inducible versions of ceramide synthesis enzymes (e.g., CERS6-FLAG, SMPD1-GFP) enables tracking and controlled expression. This is useful for studying localization and dynamics of ceramide production.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression of SPTLC1, CERS6, or SMPD1 can increase ceramide biosynthesis. Overexpression models are valuable for testing whether elevated ceramide is sufficient to induce metabolic or neurodegenerative phenotypes.
How EDITGENE Supports positive regulation of ceramide biosynthetic process Research
Researchers studying positive regulation of ceramide biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in ceramide production or merely correlated. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic manipulation and functional validation.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of ceramide biosynthetic process research.
Frequently Asked Questions About positive regulation of ceramide biosynthetic process
What is GO:2000304?
GO:2000304 is the Gene Ontology term for positive regulation of ceramide biosynthetic process, defined as any process that activates or increases the frequency, rate or extent of ceramide biosynthetic process.
What genes are involved in positive regulation of ceramide biosynthetic process?
Key genes include SPTLC1, SPTLC2, SPTLC3, KDSR, CERS1-6, DEGS1, SMPD1-3, ASAH1, ASAH2, MYC, and FGF13, among others.
How is ceramide biosynthesis upregulated?
Ceramide biosynthesis can be upregulated by increased expression or activity of serine palmitoyltransferase, ceramide synthases, or sphingomyelinases, often in response to metabolic or inflammatory signals.
What diseases are associated with dysregulated ceramide biosynthesis?
Dysregulated ceramide biosynthesis is associated with obesity, alcohol-associated liver disease, Parkinson's disease, Alzheimer's disease, breast cancer, and major depression.
What experimental models are used to study ceramide biosynthesis?
Common models include CRISPR knockout, point mutation, knock-in, and overexpression cell lines, as well as animal models and CRISPR library screening.
How can CRISPR be used to study positive regulation of ceramide biosynthesis?
CRISPR can create knockout, point mutation, knock-in, or overexpression models for genes like CERS6, SMPD1, and MYC to test their causal role in ceramide production.
What is the role of CerS6 in alcohol-associated liver disease?
CerS6 is upregulated in alcohol-associated liver disease and exhibits sex-based differences in energy homeostasis and lipid droplet accumulation.
Does exercise affect ceramide levels?
Aerobic exercise training alters systemic biomarkers including ceramide species in late middle-aged adults at risk for Alzheimer's disease.
What is the link between ceramide and Parkinson's disease?
Parkinson's disease patients with TMEM175 mutations show dysregulated lipidomic networks, and ceramide metabolism is implicated in neurodegeneration.
How does MYC regulate ceramide biosynthesis?
Intestinal MYC modulates obesity-related metabolic dysfunction and affects ceramide levels, suggesting it positively regulates ceramide synthesis.
Conclusion
The positive regulation of ceramide biosynthetic process (GO:2000304) is a critical biological process with far-reaching implications for metabolic health, neurodegeneration, and cancer. Key enzymes such as SPT, CerS, and sphingomyelinases are subject to complex regulation by genetic, nutritional, and inflammatory signals. Understanding these mechanisms offers opportunities for therapeutic intervention, and CRISPR-based models are indispensable for dissecting causal relationships. EDITGENE provides comprehensive services to support research in this field, from knockout and knock-in cell lines to library screening and bioinformatics.
References
- 1. Luo Y et al.. 2021. Intestinal MYC modulates obesity-related metabolic dysfunction.. Nat Metab 3(7):923-939 PMID: 34211180
- 2. Naderi J et al.. 2025. Ceramide-induced FGF13 impairs systemic metabolic health.. Cell Metab 37(5):1206-1222.e8 PMID: 40169001
- 3. Carrillo F et al.. 2025. Multiomics approach identifies dysregulated lipidomic and proteomic networks in Parkinson's disease patients mutated in TMEM175.. NPJ Parkinsons Dis 11(1):23 PMID: 39856101
- 4. Gaitán JM et al.. 2021. Effects of Aerobic Exercise Training on Systemic Biomarkers and Cognition in Late Middle-Aged Adults at Risk for Alzheimer's Disease.. Front Endocrinol (Lausanne) 12:660181 PMID: 34093436
- 5. Sun R et al.. 2024. Neutral ceramidase regulates breast cancer progression by metabolic programming of TREM2-associated macrophages.. Nat Commun 15(1):966 PMID: 38302493
- 6. Brazdis RM et al.. 2024. Peripheral Upregulation of Parkinson's Disease-Associated Genes Encoding α-Synuclein, β-Glucocerebrosidase, and Ceramide Glucosyltransferase in Major Depression.. Int J Mol Sci 25(6) PMID: 38542193
- 7. Shaojun Y et al.. 2024. Intervention effect of Cigu Xiaozhi prescription on ceramide lipoapoptosis in non-alcoholic fatty liver disease.. J Tradit Chin Med 44(1):63-69 PMID: 38213240
- 8. Jeon S et al.. 2023. Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation.. Mol Metab 78:101804 PMID: 37714377
